UA117455C2 - Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора - Google Patents

Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора

Info

Publication number
UA117455C2
UA117455C2 UAA201411324A UAA201411324A UA117455C2 UA 117455 C2 UA117455 C2 UA 117455C2 UA A201411324 A UAA201411324 A UA A201411324A UA A201411324 A UAA201411324 A UA A201411324A UA 117455 C2 UA117455 C2 UA 117455C2
Authority
UA
Ukraine
Prior art keywords
treatment
lung cancer
auror
application
kinas
Prior art date
Application number
UAA201411324A
Other languages
English (en)
Ukrainian (uk)
Inventor
Аріджіт Чхакраварті
Джеффрі А. Екседі
Роберт В. Клєйнфілд
Кха Н. Ле
Вен Чйі Схю
Картхік Венкатакрішнан
Original Assignee
Мілленіум Фармасьютікалз, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мілленіум Фармасьютікалз, Інк. filed Critical Мілленіум Фармасьютікалз, Інк.
Publication of UA117455C2 publication Critical patent/UA117455C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201411324A 2012-03-20 2013-03-19 Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора UA117455C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
UA117455C2 true UA117455C2 (uk) 2018-08-10

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201411324A UA117455C2 (uk) 2012-03-20 2013-03-19 Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора

Country Status (24)

Country Link
US (2) US20130303519A1 (Direct)
EP (1) EP2827855B1 (Direct)
JP (1) JP6373252B2 (Direct)
KR (1) KR102128866B1 (Direct)
CN (1) CN104271129A (Direct)
AU (1) AU2013235275B2 (Direct)
CA (1) CA2868024A1 (Direct)
EA (1) EA036434B1 (Direct)
ES (1) ES2746946T3 (Direct)
GE (2) GEP20186900B (Direct)
IL (1) IL234686B (Direct)
IN (1) IN2014DN08477A (Direct)
JO (1) JO3630B1 (Direct)
MA (1) MA37438A1 (Direct)
MX (1) MX358411B (Direct)
MY (1) MY175225A (Direct)
NZ (1) NZ700744A (Direct)
PH (1) PH12014502109A1 (Direct)
SG (2) SG11201405621UA (Direct)
TN (1) TN2014000387A1 (Direct)
TW (1) TWI649082B (Direct)
UA (1) UA117455C2 (Direct)
WO (1) WO2013142491A1 (Direct)
ZA (1) ZA201407551B (Direct)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US20190194750A1 (en) * 2015-07-02 2019-06-27 Millennium Pharmaceuticals, Inc. Biomarkers of response to selective inhibitors of aurora a kinase
CN114681455A (zh) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
CA1138863A (en) 1979-02-07 1983-01-04 Norman W. Gilman Benzazepine-derivatives
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6124281A (en) 1996-03-08 2000-09-26 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
WO1999016770A1 (en) 1997-09-29 1999-04-08 Meiji Seika Kaisha, Ltd. Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
CA2422367C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002059111A2 (en) 2000-12-21 2002-08-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
KR100909122B1 (ko) 2001-08-09 2009-07-23 액테리온 파마슈티칼 리미티드 신규한 벤조-융합된 헤테로환
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20050249806A1 (en) 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
KR20120091275A (ko) 2004-05-14 2012-08-17 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 방법
BRPI0517737A (pt) 2004-11-17 2008-10-21 Miikana Therapeutics Inc inibidores de quinase
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
BRPI0620341A2 (pt) 2005-12-23 2011-11-08 Smithkline Beecham Corparation azaindóis inibidores de cinases aurora
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
WO2008020314A2 (en) 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
BRPI0718100A2 (pt) 2006-10-31 2013-11-05 Achillion Pharmaceuticals Inc Composições farmacêuticas de elvucitabina
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
KR102080429B1 (ko) 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN104031049A (zh) * 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
GEAP201813599A (en) 2018-06-25
US10213436B2 (en) 2019-02-26
US20160193224A1 (en) 2016-07-07
MX2014011324A (es) 2014-12-05
US20130303519A1 (en) 2013-11-14
MA37438A1 (fr) 2016-05-31
EP2827855B1 (en) 2019-06-26
HK1206253A1 (en) 2016-01-08
MX358411B (es) 2018-08-20
TN2014000387A1 (en) 2015-12-21
TWI649082B (zh) 2019-02-01
SG10201607741RA (en) 2016-11-29
JO3630B1 (ar) 2020-08-27
JP6373252B2 (ja) 2018-08-15
IL234686B (en) 2020-01-30
IL234686A0 (en) 2014-11-30
AU2013235275B2 (en) 2017-12-07
KR102128866B1 (ko) 2020-07-01
IN2014DN08477A (Direct) 2015-05-08
ZA201407551B (en) 2019-01-30
EA201491727A1 (ru) 2015-01-30
KR20140144215A (ko) 2014-12-18
PH12014502109A1 (en) 2014-12-10
CN104271129A (zh) 2015-01-07
EP2827855A1 (en) 2015-01-28
EA036434B1 (ru) 2020-11-10
TW201343169A (zh) 2013-11-01
NZ700744A (en) 2016-09-30
CA2868024A1 (en) 2013-09-26
SG11201405621UA (en) 2014-10-30
WO2013142491A1 (en) 2013-09-26
ES2746946T3 (es) 2020-03-09
JP2015510945A (ja) 2015-04-13
AU2013235275A1 (en) 2014-10-23
MY175225A (en) 2020-06-16
GEP20186900B (en) 2018-10-10

Similar Documents

Publication Publication Date Title
IL289300A (en) Combination therapy for treating cancer
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
EA201400178A1 (ru) Лечение рака молочной железы
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
SI3725810T1 (sl) Kombinacijska terapija, ki vključuje protitelesa proti klavdinu 18.2 za zdravljenje raka
PT2897620T (pt) Método de tratamento de cancro
DK2922828T3 (da) 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer
EA201590997A1 (ru) Соединения и способы их применения
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201890754A1 (ru) Соединения и способы их применения
BR112014009755A2 (pt) tratamento de câncer com inibidores de quinase tor
EA201490944A1 (ru) Двойной ингибитор met и vegf для лечения рака
EP2968254A4 (en) Methods of treating lung cancer
BR112013024211A2 (pt) tratamento de tumores sólidos
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
HUE045445T2 (hu) Kombinált terápia petefészekrák kezelésére
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
EA201590656A1 (ru) Азаиндолины
EA201591709A1 (ru) 5-бром-индирубины
PL2928454T3 (pl) Triazyny do leczenia chorób wywoływanych przez pierwotniaki
UA117455C2 (uk) Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора
EP3252171B8 (en) Methods of treating cancer